As Mirati Therapeutics Inc (NASDAQ:MRTX) Price Rose, Shareholder Broadfin Capital Llc Trimmed Its Position

May 17, 2018 - By Margaret Staats

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Corporate LogoDuring 2017 Q4 the big money sentiment increased to 2.21. That’s change of 1.04, from 2017Q3’s 1.17. 10 investors sold all, 9 reduced holdings as MRTX ratio increased. 15 rose positions while 27 funds amassed positions. Funds hold 17.76 million shares thus 34.00% more from 2017Q3’s 13.25 million shares. Rock Springs Capital Limited Partnership stated it has 180,000 shs or 0.15% of all its holdings. Ecor1 Limited has invested 0.21% of its capital in Mirati Therapeutics, Inc. (NASDAQ:MRTX). State Bank Of America De reported 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Acuta Partners Ltd Liability Co holds 0.53% of its capital in Mirati Therapeutics, Inc. (NASDAQ:MRTX) for 155,000 shs. Natl Bank Of New York Mellon invested 0% of its capital in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Tower Rech Cap Lc (Trc) holds 1,572 shs. New York-based Goldman Sachs Group Inc Inc has invested 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Alphamark Ltd Limited Liability Company has 1,250 shs for 0.01% of their capital. The New York-based Citigroup Inc has invested 0% in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Putnam Invs Ltd Limited Liability Company holds 0.04% or 939,608 shs in its capital. Barclays Public Limited Com has invested 0% of its capital in Mirati Therapeutics, Inc. (NASDAQ:MRTX). Morgan Stanley accumulated 0% or 15,857 shs. State Street accumulated 0% or 714,281 shs. 510,362 were accumulated by Blackrock Inc. Eam Invsts Lc has 34,818 shs for 0.08% of their capital.

MRTX had 7 sales and 0 buys since January 11, 2018. This’s net activity of $4.97 million. On Friday, March 9 $726,040 worth of stock was sold by Christensen Jamie. $1.45M worth of Mirati Therapeutics, Inc. (NASDAQ:MRTX) shs were sold by BAUM CHARLES M.

In 2018Q1 Securities and Exchange form is reported Kevin Kotler’s holdings in Mirati Therapeutics Inc (NASDAQ:MRTX) which was reduced by 41.01%. The company’s stock rose 63.01% while stock markets declined as Broadfin Capital Llc sold 1.00 million shares. The health care company at the end of 2018Q1 was valued at $44.33M. It’s down from 2.45M at the end of the previous reported quarter. Now it had 1.44M shares held by the hedge fund run by Kevin Kotler. For a total of 2.56 million shares it increased its holding in Horizon Pharma Plc (NASDAQ:HZNP) by 2.26M shares in the quarter, and has risen its stake in La Jolla Pharmaceutical Co (NASDAQ:LJPC).

Broadfin Capital is located in New York City and was founded by Kevin Kotler. Prior to Broadfin, Kotler could be found working for firms such as ING Barings, the Galleon Group, and ABN AMRO. Broadfin Capital Llc is a New York-based hedge fund that was founded by Kevin Kotler. It had more than $1.26 billion assets under management in December, 2014. Taken from Broadfin Capital latest Adv, the fund reported to have 10 full and part-time employees. Among which 5 performing investment advisory and research functions. The hedge fund had between 1-10 clients.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Ratings Coverage

Total analysts of 5 have positions in Mirati Therapeutics (NASDAQ:MRTX) as follows: 5 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since December 21, 2017 according to StockzIntelligence Inc Mirati Therapeutics has 5 analyst reports. On Thursday, December 21 the firm has “Buy” rating by Cowen & Co given. On Monday, March 5 the firm has “Buy” rating by Citigroup given. In Thursday, March 8 report SunTrust maintained the stock with “Buy” rating. On Wednesday, April 25 the company was maintained by H.C. Wainwright.

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products.The firm is worth $1.03 billion. The company's clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.Currently it has negative earnings. The Company’s clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: